Climb Bio (CLYM) Research & Development (2020 - 2026)
Climb Bio's (CLYM) quarterly Research & Development came in at $9.4 million in Q1 2026, down 45.91% YoY from $17.3 million in Q1 2025, and down 31.77% on a QoQ basis from $13.7 million in Q4 2025.
Climb Bio (CLYM) Research & Development (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Research & Development data on file, last reported at $9.4 million in Q1 2026.
- Quarterly Research & Development fell 45.91% year-over-year to $9.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $38.8 million (up 26.78% YoY) and the FY2025 annual result came in at $46.7 million, up 225.84% from the prior year.
- Research & Development declined to $9.4 million in Q1 2026, from $13.7 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $17.3 million in Q1 2025 to a low of $1.0 million in Q2 2024.
- A 5-year average of $6.6 million and a median of $6.0 million in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2024 — Research & Development plunged 80.93% — and 2025, when it soared 1488.18%.
- Tracing CLYM's Research & Development over 5 years: stood at $4.9 million in 2022, then slumped by 36.53% to $3.1 million in 2023, then surged by 90.57% to $6.0 million in 2024, then jumped by 130.54% to $13.7 million in 2025, then tumbled by 31.77% to $9.4 million in 2026.
- The last three Research & Development figures came in at $9.4 million (Q1 2026), $13.7 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 9.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.71 Mn |
| Mar 31, 2026 | 9.37 Mn |
| Dec 31, 2025 | 13.74 Mn |
| Sep 30, 2025 | 9.07 Mn |
| Jun 30, 2025 | 6.58 Mn |
| Mar 31, 2025 | 17.33 Mn |
| Dec 31, 2024 | 5.96 Mn |
| Sep 30, 2024 | 6.24 Mn |
| Jun 30, 2024 | 1.05 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 3.13 Mn |
| Sep 30, 2023 | 2.88 Mn |
| Jun 30, 2023 | 3.69 Mn |
| Mar 31, 2023 | 5.72 Mn |
| Dec 31, 2022 | 4.93 Mn |
| Sep 30, 2022 | 4.26 Mn |
| Jun 30, 2022 | 8.77 Mn |
| Mar 31, 2022 | 8.26 Mn |
| Dec 31, 2021 | 6.88 Mn |
| Sep 30, 2021 | 5.99 Mn |